Related Experiment Video
Updated: Sep 19, 2025
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple
Fumou Sun1,2, Yan Cheng2, Catherine Ma2,3
1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract:
BackgroundMultiple myeloma (MM) is virtually always preceded by monoclonal gammopathy of undetermined significance (MGUS). Elevated serum markers are used to classify MGUS patients into clinical risk categories. Previous research has indicated that the absence of a normal plasma cell signature in MGUS is linked to early progression.ObjectiveTo confirm that the presence of a "polyclonal plasma cell (PolyPC) signature" serves as a robust negative predictor of MGUS progression.Methods374 MGUS patients were enrolled, including 334 patients with stable disease and 40 patients who progressed to MM within 10 years. An oligonucleotide microarray analysis was performed on mRNA extracted from CD138-selected bone marrow plasma cells to evaluate gene expression profiles. The PolyPC signature was developed and validated to assess its role in predicting disease progression. Statistical analyses included Cox proportional hazards models to evaluate progression risk and receiver operating characteristic (ROC) curve analysis to determine the sensitivity, specificity, and overall predictive performance of the PolyPC score.ResultsThrough this retrospective study, we developed PolyPC signature based on gene expression profiles of normal, uninvolved plasma cells to predict MGUS progression risk. ROC analysis demonstrated that this signature accurately predicted the risk of MGUS progression (C-statistic: 0.792). A PolyPC score ≤ 11.6 identified a subset of 89 patients with a 10-year progression probability of 31.5% (28/89), while the remaining 285 patients had a progression probability of only 4.2% (12/285) (p < 0.01). Sensitivity and specificity were 70% (28/40) and 81.7% (273/334). The external validation using the SWOG-S0120 dataset reinforces the robustness and clinical applicability of the PolyPC score in predicting MGUS progression to MM.ConclusionsThe strength of the PolyPC signature is a powerful negative predictor of MGUS progression. These findings support incorporating PolyPC into MGUS management to identify patients needing more frequent and intensive monitoring.
Insights
The polyclonal plasma cell (PolyPC) signature effectively predicts which patients with monoclonal gammopathy of undetermined significance (MGUS) will not progress to multiple myeloma. This finding supports using the PolyPC signature for better MGUS patient management and monitoring.
Area of Science:
- Hematology
- Oncology
- Genomics
Background:
- Multiple myeloma (MM) development is preceded by monoclonal gammopathy of undetermined significance (MGUS).
- Current risk stratification for MGUS relies on serum markers.
- Prior research suggests a lack of normal plasma cell signature correlates with early MM progression.
Purpose of the Study:
- To validate the polyclonal plasma cell (PolyPC) signature as a negative predictor of MGUS progression.
- To assess the PolyPC signature's utility in identifying patients at low risk of progressing to MM.
Main Methods:
- Gene expression profiling using oligonucleotide microarrays on bone marrow plasma cells from 374 MGUS patients.
- Development and validation of the PolyPC signature using CD138-selected plasma cells.
- Statistical analysis including Cox proportional hazards models and ROC curve analysis.
Main Results:
- The PolyPC signature accurately predicted MGUS progression risk (C-statistic: 0.792).
- A low PolyPC score (≤11.6) identified patients with significantly lower 10-year progression probability (4.2%) compared to higher scores (31.5%).
- High sensitivity (70%) and specificity (81.7%) were achieved in predicting progression.
Conclusions:
- The PolyPC signature is a powerful negative predictor for MGUS progression to multiple myeloma.
- Incorporating the PolyPC signature into MGUS management can help identify patients requiring less intensive monitoring.
- This approach aids in refining patient stratification and resource allocation in MM surveillance.
